XP-828L (Dermylex), a new whey protein extract with potential benefit for mild to moderate psoriasis.
Natural health products (NHPs) or complementary and alternative medicine (CAM) are commonly used to prevent disorders or support the usual treatments of many diseases. XP-828L, a whey protein extract, has demonstrated potential benefits for the treatment of mild to moderate psoriasis. The aim of this study was to analyze further clinical data that demonstrated the clinical benefits and safety of the XP-828L in patients with psoriasis and the potential mechanism of action of this product in vitro. Oral administration (2.5 g, twice a day, over 112 days) of XP-828L in 42 human subjects with mild to moderate psoriasis improved their PGA scores (physician's global assessment). Moreover, no significant changes in haematology or hepatic and renal parameters were observed throughout the study period, indicating the safety of the product. In vitro experiments showed that XP-828L decreased the proliferation of concanavalin A (ConA)-stimulated murine splenocytes and their production of interleukin (IL)-2 and interferon (IFN)-gamma. Although the in vivo mechanism of action of XP-828L remains unknown, XP-828L represents an NHP to be used as an alternative or concomitant treatment for mild to moderate psoriasis and potentially for other immune-mediated diseases.
Drouin
Réjean
R
Advitech Inc., 1165, boulevard Lebourgneuf, Suite 140, Québec, QC G2K2C9, Canada.
Lamiot
Eric
E
Cantin
Kim
K
Gauthier
Sylvie F
SF
Pouliot
Yves
Y
Poubelle
Patrice E
PE
Juneau
Christina
C
D000328:Adult; D000368:Aged; D000818:Animals; D049109:Cell Proliferation / Q000187:drug effects; D016207:Cytokines / Q000378:metabolism; D005260:Female; D006801:Humans; D066298:In Vitro Techniques; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D008875:Middle Aged; D008894:Milk Proteins / Q000627:therapeutic use*; D011565:Psoriasis / Q000188:drug therapy*; D013154:Spleen / Q000166:cytology
D016207:Cytokines; D008894:Milk Proteins; C518519:XP-828l